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Abstract
Background/Aim. It has been observed that a large num-
ber of patients with low urinary tract symptoms due to be-
nign prostatic hyperplasia (LUTS/BPH)) has been treated
with a combination of tamsulosin (TAM) + Serenoa repens
(SR) (TAM + SR). The aim of this study was to compare a
combination TAM + SR with TAM and SR alone, to see if
there was any difference in efficacy and tolerance of each in
patients with LUTS/BPH. Methods. In this prospective
study patients had to have prostate volume (PV) < 50 mL,
International Prostate Symptom Score (IPSS) of 7–18,
Quality of Life score (QoLs) > 3, a maximal flow rate
(Qmax) of 5–15 mL/s, with post voiding residual volume
(PVR) < 150 mL and serum prostatic antigen (PSA) < 4
ng/mL. TAM (0.4 mg) was administered once a day, SR
(320 mg) daily or SR (320 mg) + TAM (0.4 mg) daily for a
median period of 6 months. Results. A total of 297 patients
were recruited, whereas 265 patients were fully available: 87
into the group TAM, 97 into the group SR and 81 into the
group TAM + SR. There was no statistically significant dif-
ference between the treatment groups in the sense of
demographic and other baseline parameters. No difference
was found among the 3 treatment groups, neither in the
major endpoint of the study in the sense of a change be-
tween baseline and final evaluation in total IPSS, obstructive
and irritative subscores, improvement of QoLs, increase in
Qmax, nor for the second endpoint including diminution of
PV, PSA and PVR. During the treatment period 20 (23%)
of the patients managed with TAM and 17 (21%) with TAM
+ SR had drug- treated with related adverse reactions. No
adverse effect was detected in the group SR. Conclusion.
Treatment of BPH by both SR and TAM seems to be effi-
cacious alone. None of them had superiority over another
and, additionally, a combined therapy (TAM + SR) does not
provide extra benefits. Furthermore, SR is a well-tolerated
agent that can be used alternatively in the treatment of
LUTS/BPH.
Key words:
prosthatic hyperplasia; adrenergic alpha-antagonists;
phytotherapy; treatment outcome.
Apstrakt
Uvod/Cilj. Uoÿeno je da veliki broj bolesnika sa simpto-
mima od strane donjih partija urotrakta izazvanih benignom
hiperplazijom prostate (SDPU/BHP) ima terapiju sa kom-
binacijom tamsulosina (TAM) + Serenoa repens (SR) (TAM +
SR). Ova studija imala je za cilj da uporedi kombinaciju
TAM + SR sa samo TAM i SR, da bi se videlo da li postoji
razlika izmeĀu njih u pogledu efikasnosti i podnošljivosti
kod bolesnika sa SDPU/BHP. Metode. U ovoj prospektiv-
noj studiji bolesnici su imali volumen prostate (VP) < 50
mL, internacionalni prostata simptom skor (IPSS) 7–18,
ocenu kvaliteta života (KŽ) > 3, maksimalni protok urina
(MPU) 5–15 mL/s, sa volumenom rezidualnog urina (RU)
< 150 mL i prostata specifiÿnim antigenom (PSA) < 4
ng/mL. TAM (0,4 mg) je bio primenjivan jedan put dnevno,
SR u dozi od 320 mg dnevno, a kombinacija SR (320 mg) +
TAM (0,4 mg) dnevno za proseÿni period od 6 meseci. Re-
zultati. Ukupno 297 bolesnika bilo je ukljuÿeno u studiju, s
tim da je 265 bolesnika bilo dostupno potpunoj proceni: 87
u TAM grupi, 97 u SR grupi i 81 u TAM + SR grupi. Nije
bilo statistiÿki znaÿajne razlike izmeĀu grupa u pogledu de-
mografskih i drugih parametara pri poÿetnoj proceni. Tako-
Āe, nije bilo razlike izmeĀu tri grupe, kako u pogledu pri-
marnog cilja studije, promene izmeĀu poÿetne i završne
ocene ukupnog IPSS, opstruktivnom i nadražujuýem sup-
skoru, poboljšanju KŽ, poveýanju MPU, kao ni u pogledu
sekundarnog cilja studije ukljuÿujuýi smanjenje VP, PSA i
RU. Tokom leÿenja, 20 (23%) bolesnika leÿenih TAM i  17
(21%) bolesnika na kombinaicji TAM + SR imali su neže-
ljene reakcije. Nije bilo neželjenih sporednih efekata u grupi
SR. Zakljuÿak. Leÿenje BPH sa SR i TAM je podjednako
efikasno. Ni jedan od tretmana nema superiornost u odnosu
na drugi i dodatno, kombinovana terapija (TAM + SR) ne
doprinosi dodatnom poboljšanju efikasnosti. Štaviše, izgleda
da je SR dobro podnošljiv fitopreparat koji se može alterna-
tivno primeniti u leÿenju SDPU/BHP.
Kljuÿne reÿi:
prostata, hipertrofija; alfa blokatori; fitoterapija;
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Introduction
Low urinary tract symptoms (LUTS) are frequently as-
sociated with benign prostatic hyperplasia (BPH) caused by
cellular hyperplasia of both glandular and stromal elements.
With an aging population the number of men affected by
BPH is likely to increase 
1, 2. Symptoms severity appears to
be dependent, at least in part, on smooth muscle tone in the
prostate and bladder neck ³. Since medical inhibitors, in-
cluding alpha-blockers (ABs) 
4, alpha-reductase inhibitors
(5-ARIs) and phytotherapeutic agents offer an attractive al-
ternative to surgery, the number of transurethral resections of
the prostate has declined in recent years 
5, 6. However, the
tolerability of these agents varies. Some ABs are associated
with cardiovascular adverse events (AEs) (postural hypoten-
sion, dizziness, and headache) and 5-ARIs can lead to sexual
dysfunction 
7.  Conversely, a drug with high affinity for al-
pha 1A-adrenoreceptors (tamsulosin) (TAM) may be more
prostate specific and may maintain the therapeutic response
in the treatment of symptomatic BPH with less effect on
blood pressure and fewer cardiovascular AEs 
8. In selected
patients, a combination of AB and 5-ARI is the most effec-
tive form of BPH medical therapy to reduce the risk of clini-
cal progression, i.e. acute urinary retention (AUR) and BPH-
related surgery 
9. On the other hand, increasing attention has
been focused on the use of phytotherapeutic agents to allevi-
ate the symptoms of BPH. The most described and studied
phytotherapeutic agent for the medical treatment of BPH is
etahnolic extract of Serenoa repens (SR) (Sabal serrulata)
derived from the berry of the American dwarf palm tree 
10–12.
The antiandrogenic, antiproliferative and anti-inflammatory
complementary activities of SR extracts could constitute an
advantage over ABs to treated symptomatic BPH where both
“obstruction” and “irritation” are involved.
The aim of this prospective pilot study was to test the
hypothesis that the efficacy of combination TAM + SR is su-
perior to TAM and SR alone for the relief of LUTS/BPH.
The main endpoints of the study were changes in the total
International Prostate Symptom Score (IPSS), Quality of a
life score (QoLs), maximal flow rate (Qmax) and post void-
ing residual volume (PVR) from baseline to the last observa-
tion carried forward. This was applied only in naive patients
suffering from LUTS/BPH without previous treatment with
ABs, 5-ARIs or phytotherapy.
Methods
Between June 2008 and September 2010, 297 men aged
50–87 years, with symptomatic BPH were included in the
study containing 3 regimens: TAM (Tamsol
®) 0.4 mg daily
(n = 98), SR (Prostamol uno
®) and TAM 0.4 mg + SR 320
mg daily (n = 92), to compare the efficacy of each of these
treatment regimens. All the patients signed informed consent
form before any treatment. Pre-treatment procedures con-
sisted of collection of the medical history (including urologic
history), check of concomitant medications, physical exami-
nation [including digital rectal examination (DRE)], routine
laboratory tests [urine analysis, urine culture, creatinine,
prostate specific antigen (PSA)], total IPSS, irritative and ob-
structive  subscores, QoLs, prostate volumen (PV), Qmax
and PVR. The study was specially designed for medical
treatment of patients suffering from low risk of AUR and
BPH-related surgery. Inclusion criteria were men > 50 years
of age, a total IPSS of 7–18, QoLs >3, Qmax of 5–15 mL/s,
with PVR < 150 mL, PV < 50 mL, measured by transrectal
ultrasound (TRUS) and serum PSA 1.5–4 ng/mL. TRUS-
guided biopsies of the prostate were performed in patients
with PSA > 4 ng/mL, abnormal DRE, and/or suspicious
echogenicity on TRUS. The subjects with a significant blad-
der outlet obstruction (BOO) were excluded a priori from
the study (PVR > 200 mL, Qmax < 5 mL/s). Patients were
excluded from the study if they had the history of bladder
disease likely to affect micturition, urethral stenosis, prostate
and/or bladder cancer, bladder stone, previous pelvic radio-
therapy, recurrent urinary retention, neurogenic lower uri-
nary tract dysfunction, repeated infection of the urinary tract,
chronic bacterial prostatitis, or any other disease that can
cause urinary problems. Assessment visits were performed
head to head and were scheduled at randomization (day 0),
and latter at months 3 and 6. PV and PSA were measured at
selection and at endpoint, whereas the total IPSS, obstructive
and irritative subscore, Qols, Qmax and PVR were evaluated
at baseline and later every 3 months. Responders were de-
fined on the basis of IPSS and Qmax by decrease of > 25%
and increase of > 30% from baseline, respectively. The pa-
tients without subjective and objective improvement were
rejected from the study within 3 months from the initiation of
the treatment, after both patients and physicians had agreed
about that.
The Kruskal-Wallis test was used for comparison of the
groups and the Wilcoxon signed-rank test for analysis of the
baseline and a 6-month treatment parameters. A p value <
0.05 was considered statistically significant. Data processing
was done by SPSS package for Windows version 11.0.
Results
A total of 87, 97 and 81 patients were fully available
regarding the treatment regimen, according to TAM, SR
and TAM + SR, respectively. The main reason for study
discontinuation was voluntary withdrawal (1.3%), protocol
violation (2.4%), lack of efficacy (3.03%) and other rea-
sons (2.7%). Four (1.3%) patients were lost to follow-up
(Table 1).
The treatment groups had comparable distribution in
terms of age, body mass index, a total IPSS, irritative and
obstructive subscores, QoLs, Qmax, PVR, PV and PSA (Ta-
ble 2). The mean age was 64.9 ± 7.6 years.
After 6 months of the treatment, the mean decrease in
IPSS was -4.6, -6.1 and -4.9 in the TAM, SR and TAM + SR
groups respectively. The difference between IPSS values at
baseline and 6 months later were significant in each group (p
< 0.05). The patients in the group SR had a greater reduction
in symptoms than the other group. However, statistical
analysis did not reveal this expected difference between the
treatment regimens (p = 0.1). This difference between theVolumen 70, Broj 12 VOJNOSANITETSKI PREGLED Strana 1093
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groups in the mean total IPSS decrease was not observed in
the irritative part -1.7, -1.8 and -1.9 (p = 0.6) and the obstruc-
tive part -1.5, -1.4 and -1.3 (p = 0.5), for TAM, SR and TAM
+ SR, respectively. For the QoLs, the group TAM had an ini-
tial mean score of 3.5, which decreased for 2.1; the group SR
4.2 which decreased to 2.6; the group TAM + SR had the ini-
tial mean score of 3.5 which decreased for 2.2 after 6 months.
The 3 groups had lower mean score after the treatment but the
difference was not significant (p = 0.1). Six months following
the treatment, the mean increase in Qmax was similar in both
TAM and SR group (3.7 mL/s for TAM, 3.2 mL/s for SR), but
was slightly greater in the group TAM + SR (4.2 mL/s). The
patients in each group improved flow rates and the difference
between the Qmax values at baseline and 6 months later was
statistical significance in each group (p < 0.005), although the
difference was not statistically significant among groups with
regard to increase in Qmax values (p = 0.3). The improvement
of PVR volume was not statistically different among the
groups which decreased by 29.6, 28.1 and 25.4 mL, respec-
tively (p = 0.4). Six months following the treatment the mean
PV had decreased by 1.0, 0.7 and 0.8 mL, respectively. The
difference was not significant (p = 0.6). The decrease in PSA
was more pronounced in the groups SR, but the difference was
not statistically significant (p = 0.25) (Table 3).
Table 3
Mean changes and ameliration rate in efficacy parameters from baseline to endpoint of the study
Parameters TAM (n = 87) SR (n = 97) TAM + SR (n = 81) p
IPSS total score, ʉ ± SD
[amelioration rate (%)]
- 4.6 ± 3.3,
(28.4)
- 6.1 ± 2.7,
(33.9)
- 4.9 ± 2.3,
(31.4) 0.1
IPSS obstructive subscore, ʉ ± SD
[amelioration rate (%)]
-1.5 ± 2.4,
(16.7)
-1.4 ± 3.1,
(13.8)
-1.3 ± 2.8,
(15.1) 0.5
IPSS irritative subscore, ʉ ± SD
[amelioration rate (%)]
-1.7 ± 2.8,
(26.6)
-1.8 ± 0.9,
(26.9)
-1.9 ± 9.4,
(28.8) 0.6
QoL  score, ʉ ± SD
[amelioration rate (%)]
- 2.1 ± 0.8,
(60)
-2.6 ± 0.9,
(61.9)
- 2.2 ± 1.0,
(62.9) 0.1
Qmax (mL/s), ʉ ± SD
[amelioration rate (%)]
+3.7 ± 2.6,
(35.2)
+3.2 ± 2.2,
(34.1)
+4.2 ± 2.5,
(42.4) 0.3
PVR (mL), ʉ ± SD
[amelioration rate (%)]
- 23.6 ±20.2,
(36.0)
-28.1 ± 22.6,
(41.7)
-25.4 ± 14.8,
(39.9) 0.4
PV (mL), ʉ ± SD
[amelioration rate (%)]
- 1.0 ± 0.6,
(2.6)
-0.7 ± 0.1,
(2.0)
- 0.8 ± 0.3,
(2.6) 0.6
PSA (ng/mL), ʉ ± SD
[amelioration rate (%)]
- 0.1 ± 0.2,
(4.8)
-0.3 ± 1.4,
(15)
- 0.25 ± 0.2,
(14.7) 0.25
SD – standard deviation, TAM – tamsulosin; SR – Serenoa repens; IPPS – International Prostate Symptom Score; QoL – Quality of life; Qmax – maximal flow
rate; PVR – post-voiding residual volume; PV – prostate volume; PSA – prostate specific antigen.
Table 1
Reasons for premature discontinuation per the treatment group
Variable TAM (n = 98)
n (%)
SR (n = 107)
n (%)
TAM + SR (n = 92)
n (%)
Completed study treatments 87 (88.8) 97 (80.7) 81 (88.0)
Discontinued study treatment 11 (11.2) 10 (9.3) 11 (12)
Lost to follow-up 1 (1.02) 1 (0.9) 2 (2.2)
Discontinued due to:
protocol violation 3 (3.06) 2 (1.8) 2 (2.2)
patient’s decision 2 (2.04) 1 (0.9) 1 (1.1)
other reasons 2 (2.04) 2 (1.8) 4 (4.4)
lack of efficacy 3 (3.06) 4 (3.6) 2 (2.2)
TAM – tamsulosin; SR – Serenoa repens; n – number of patients.
Table 2
Demographic and other baseline parameters (ʉ ± SD)
Parameters TAM (n = 87) SR (n = 97) TAM + SR (n = 81) p
Age (years) 56.8 ± 7.7 59.2 ± 7.8 65.9 ± 7.4 0.27
Body mass index (kg/m
2) 28.0 ± 3.4 26.7 ± 2.5 27.8 ± 2.3 0.40
IPSS total score 16.2 ± 4.7 18.0 ± 4.9 15.6 ± 3.2 0.21
IPSS obstructive subscore 9.0 ± 3.5 10.1 ± 4.2 8.6 ± 3.2 0.85
IPSS irritative subscore 6.4 ± 2.8 6.7 ± 3.1 6.6 ± 2.5 0.91
QoL score 3.5 ± 1.1 4.2 ± 1.2 3.5 ± 1.1 0.08
Qmax (mL/s) 10.5 ± 2.8 9.4 ± 2.9 9.9 ± 2.4 0.49
PVR (mL) 65.5 ± 33.3 67.4 ± 27.7 63.7 ± 23.7 0.76
PV (mL) 38.6 ± 11.6 35.2 ± 10.3 31.2 ± 4.2 0.07
PSA (ng/mL) 2.1 ± 0.9 1.9 ± 0.9 1.7 ± 0.7 0.41
SD – standard deviation, TAM – tamsulosin; SR – Serenoa repens; IPPS – International Prostate Symptom Score; QoL – Quality of life; Qmax – maximal flow
rate; PVR – post-voiding residual volume; PV – prostate volume; PSA – prostate specific antigen.Strana 1094 VOJNOSANITETSKI PREGLED Volumen 70, Broj 12
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At endpoint, the percentage of patients negatively af-
fected by urinary symptoms (feeling mostly dissatisfied, un-
happy, and terrible) was reduced by > 50% in the groups
TAM, SR and TAM + SR (from 66.7% to 34.5%, from
63.1% to 34.7% and from 64.2% to 22.7%, respectively) (p <
0.001) (Table 4).
During a 6-month treatment period, 20 (23%) of the
patients managed with TAM and 17 (21%) patients with
TAM + SR, had some degree of drug related AEs. For most
of these patients (79%) the AEs were mild. The most fre-
quently reported AEs were reduced or absent ejaculations
during orgasm and a headache. The mean improvement of
total IPSS was greater in the men experiencing ejaculatory
disorders (10.7%) than in those who did not (-7.3 ± 3.3 vs -
6.1 ± 2.3) (p = 0.04) but not regarding Qmax (-4.0 ± 2.3 vs -
3.4 ± 2.5) (p = 0.07). A headache was reported by a slightly
higher percentage of subjects in the group TAM + SR (6.1%)
compared to the group TAM (5.9%), but without statistically
significant difference. However, these AEs did not result in
withdrawal from the study. No AE, were detected in the
group SR (Table 5).
Discussion
The use of phytotherapy in treating LUTS/BPH has
been popular in Europe for many years and has recently
spread in the USA. In some studies the efficacy of SR was
found to be equivalent to 5-ARI and Abs ¹²
, ¹³. However, re-
cently updated Cochrane report summarized the clinical re-
sults of 30 randomized trials comprising 5.222 men. SR was
compared as mono or combination preparations either with
placebo, other plant extracts (Pygeum africanum, Ustica di-
oica), the 5-ARI (finasteride), or AB (TAM). The mean fol-
low-up of these trials varied between 4 and 60 weeks. The
Cochrane report concluded that SR was not superior to pla-
cebo, finasteride, or TAM with regard to IPSS improvement,
increase in Qmax or prostate size reduction. For nocturia SR
was significantly better than placebo (mean weight differ-
ence -0.78) 
14.
Direct comparative randomized controlled trials have
shown the superior efficacy of ABs over placebo, whereas
the combination of 5-ARI and an AB was more effective
than the AB alone 
15. Although the combination of an AB
and SR was frequently used in some European countries, in-
cluding Serbia, at the time of preparing this study, its supe-
rior efficacy over AB and SR alone had not been fully inves-
tigated. Therefore, this question was addressed to direct
comparative trial.
The results of our study demonstrate that TAM and SR
are equivalent to a combination TAM + SR in the manage-
ment of these patients. After 6 months, all the treatment
groups induced practically the same mean reduction in total
IPSS (-4.6 vs -6.1 vs -4.9 points) with 2/3 of men responding
to the treatment by a decrease of 3 points or more. For all the
treatment groups the mean percentage change from baseline
and after 6- months was similar (28.4% for TAM, 33.9% for
SR and 31.4% for TAM + SR).  This data correlates with the
results reported in other series 
14, 16. However, the difference
in total IPSS in TAM vs the group TAM + SR was slightly
higher in the study of Glemain et al. 
17 (-5.2 vs -6.0). The
greatest improvement in total IPSS was observed in those
patients with greatest severity of disease 
18. No differences
were observed among the treatment groups from baseline to
Table 4
Summary of quality of life scores related to urinary simptoms
Variable TAM (n = 87)
n (%)
SR (n = 97)
n (%)
TAM + SR (n = 81)
n (%)
Baseline
Delighted, pleased or mostly satisfied 7 (8.0) 9 (8.1) 7 (8.6)
Mixed: about equally satisfied and unsatisfied 22 (25.3) 28 (28.6) 22 (27.2)
Mostly dissatisfied, unhappy or terrible 58 ( 66.7) 60 (63.1) 52 (64.2)
Endpoint
Delighted, pleased or mostly satisfied 38 (43.7) 42 (44.2) 36 (44.4)
Mixed: about equally satisfied and unsatisfied 19 (21.8) 22 (23.2) 21 (25.9)
Mostly dissatisfied, unhappy or terrible 30 (34.5) 33 (34.7) 24 (22.7)
n – number of patients; TAM – tamsulosin.
Table 5
Adverse events summary
Parameters TAM (n = 87) SR (n = 97) TAM + SR (n = 81)
Any, n (%) 67 (77.0) 97 (100) 64 (79.0)
Rhinitis, n 1 – –
Fatigue, n 1 – –
Dizziness, n 1 – 1
Postural hypotension, n 1 – 1
Dry mouth, n 1 – 1
Libido decrease, n 1 – 1
Ejaculation disorders, n 10 – 8
Headache, n 4 – 5
Total adverse events, n (%) 20 (23.0) – 17 (21.0)
TAM – tamsulosin; SR – Serenoa repens; n – number of patients.Volumen 70, Broj 12 VOJNOSANITETSKI PREGLED Strana 1095
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endpoint of the study in terms of irritative and obstructive
symptoms, corresponding with data providing from other
studies
 16, 17.
We reported the improvement in QoLs of -2.1, -2.6 and
-2.2 in each group. However, the improvement of QoLs was
lower for TAM vs TAM + SR, -1.0 vs -1.3, in the study re-
ported by Glemain et al. 
17.
In the present study, the mean increase in Qmax (3.7
mL/s, 3.2mL/s and 4.2 mL/s) strongly correlates with data
providing from Hizli and Uygur 
16, whereas mean changes of
1.3mL/s (TAM) and 1.2mL/s (TAM+SR) are reported in
other study 
17.
Limited studies have evaluated PVR in measuring the
response to treatment 
16. We measured PVR to assess the ef-
ficacy of treatment regimens and found a mean decrease of
23.6 mL, 28.1 mL and 25.4 mL, respectively.
We found that the addition of SR has no significant ef-
fect on PSA levels, consistent with earlier results 
19. In fact,
decreasing PSA would not be a desire result of a BPH medi-
cation, because it may mask or delay the detection of pro-
static carcinoma. This is in contrast with 5-ARI 
15.
PV was found to be decreased by SR in 3 uncontrolled
stdies 
20–22, but this was not confirmed in controlled stud-
ies 
10, 11.We found the mean decrease in PV of -1.0 mL, -0.7
mL and 0.8 mL for the groups TAM, SR and TAM + SR, re-
spectively, but they were not statistically significant. TAM ef-
ficacy does not depend on prostate size and is similar across
age group. However, TAM does not reduce prostate size 
23.
The occurrence of AEs was similar in the groups TAM
and TAM + SR (23% vs 21%). Retrograde ejaculation was
the most common TAM related AE (10.7%). The mean im-
provement of IPSS was greater in the men experiencing this
AE than in the men who did not. For the older BPH patients
who experienced retrograde ejaculation, it might be a small
trade for the rapid and significant relief of urinary symptoms
that treatment with TAM offered. Retrograde ejaculation is a
characteristic AE of ABs with the occurrence in 4%–11% of
patients and that has been shown to be reversible after ad-
ministration of the drug has been stopped 
24. In short, our re-
sults confirm that AEs are commonly associated with TAM,
whereas SR is a well-tolerated agent used for LUTS/BPH.
The best of our knowledge shows that only one study
has compared TAM and SR alone with combination of TAM
+S R in treatment of LUTS/BPH 
16, 17. The number of 60 pa-
tients included in this study (20 in each group) with follow-
up of 6 months, is too small to be absolutely confident about
these results. The OCOS trial included 329 patients managed
with TAM (n = 161) and TAM + SR (n = 168) with the mean
follow-up of 52 weeks. No statistically significant difference
was found between these groups, neither for the change in
IPSS between the baseline and final evaluation, nor for the
improvement of the irritative and obstructive subscore, QoLs
and Qmax. However, the group SR was not included in this
study 
17.
Although the efficacy of the 3 treatment groups can
only be reliably determined with placebo-controlled stud-
ies, clinically relevant information can still be gained from
comparative trials, and for this reason a placebo group was
not included in the present study. The follow-up was rela-
tively short (6 months) in comparison to 12 months in other
trials 
11, 14, 17. There is also a financial implication with the
use of SR because reimbursement of cost by health insurance
in Europe, including Serbia, is not contemplated. However,
trials exploring efficacy of new AB silodosin have a follow-
up of only 3 months 
25, 26. We investigate currently the com-
bination of AB with phytotherapeutical agent isoflavone ex-
tracted from red clover (trifolium pretense) during the treat-
ment period of 3 months in patients with mild and moderate
symptomatic BPH.
Overall, it appears that phytotherapy with SR is as valid
pharmacotherapy as Abs in management of men with
LUTS/BPH. Indeed, it may have less adverse effects and be
better tolerated. What is certain is that urologist should be
aware and informed about phytotherapy as it inevitably be-
comes part of the standard medical therapy for men with
LUTS/BPH.
Conclusion
We find that treatment of BPH with both TAM and SR
alone seems to be equally effective in reducing urinary ob-
struction, in proving symptomatology and QoLs, whereas a
combined therapy (TAM + SR) does not provide extra bene-
fits. Furthermore, SR is a well-tolerated agent that can be
used alternatively in treatment of LUTS/BPH. The limitation
of our study is a relatively short follow-up. Large prospective
randomized studies with longer follow-up periods are needed
to clarify more the efficacy of SR in treatment of BPH.
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